Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Online First
FDA Updates
Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma
Read More
Online First
FDA Updates
Olaratumab Approved for Use with Doxorubicin in Adults with Advanced Soft-Tissue Sarcoma
Read More
Online First
FDA Updates
Atezolizumab First PD-L1 Inhibitor Approved for the Treatment of Patients with Metastatic NSCLC
Read More
The Importance of Monitoring Cardiotoxicity in Patients with Breast Cancer
Sandra Cuellar Puri, PharmD, BCOP
Read More
Original Research
The Effect of Written Pharmacist-Provided Patient Education for 3 Frequently Prescribed Oral Anticancer Agents on the Incidence of Patient-Initiated Triage Calls
Nicolas De Padova, PharmD
,
Robert Grabowski, PharmD
,
Joseph Ineck, PharmD, CPE
,
Robert Mancini, PharmD, BCOP, FHOPA
Read More
Supportive Care
HER2 Receptor Antagonist–Associated Cardiotoxicity
Alison Palumbo, PharmD, MPH, BCOP
,
Joseph Bubalo, PharmD, BCPS, BCOP
Read More
Overview of the Current Treatment Paradigm in Chronic Lymphocytic Leukemia, Part 2
Austin J. Combest, PharmD, BCOP, MBA
,
Ryan C. Danford, PharmD
,
Elizabeth R. Andrews, PharmD
,
Ashley Simmons, PharmD
,
Paulina McAtee, PharmD
,
Dirk J. Reitsma, MD
Read More
Lung Cancer
Adjusted Dosing and Schedule of Pemetrexed in Impaired Renal Function
Zahava Ohana, PharmD
,
Amanda Brahim, PharmD, BCPS
,
Mohammed Ibrahim, RPh, BCOP, BCPS, BCACP
Read More
From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Read More
FDA Updates
Pembrolizumab Approved for Patients with Head and Neck Cancer
Read More
165
166
167
168
169
170
171
Page 168 of 196
Results 1671 - 1680 of 1955